Therapeutic Drug Monitoring in tuberculosis patients. Setup and optimisation of therapeutic drug monitoring at the Research Center Borstel

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009869

Enrollment

Registered

2016-01-13

Start date

2016-01-18

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A15.9

Interventions

Group 1: Multidrug resistant (MDR) tuberculosis (TB) is one of the most challenging emerging infectious diseases of our time. Inadequate anti-TB-drug dosage due to pharmacokinetic variablitiy between

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: pan-susceptible, MDR and XDR Tuberculosis

Exclusion criteria

Exclusion criteria: Currently pregnant or breastfeeding, participation/enrollement not feasible according to a physician, unable to provide informed consent, no consent obtained

Design outcomes

Secondary

Measure	Time frame
No secondary outcome.	—

Primary

Measure	Time frame
To establish the HPLC-MS-MS-based method for measuring drug concentrations and identify the optimal sampling strategy.	—

Countries

Germany

Contacts

Public ContactChristoph Lange

Medizinische Klinik des Forschungszentrums Borstel

clange@fz-borstel.de0049 4537 188 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026